GlassScriptPhysician profile
Katelyn Polilli
NPI 1891328092
$2,407.91
in general payments reported to CMS, 2019-2025
19 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $347 · 2023: $979 · 2024: $707 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.07 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $394.05 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $298.07 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $255.26 | 2021-2024 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $244.52 | 2023-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $231.96 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $218.51 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.37 | 2023-2024 | Jardiance |
| Scpharmaceuticals INC. | $136.95 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $119.21 | 2021-2024 | Atacand, Farxiga |
| Revance Therapeutics, INC. | $106.59 | 2025 | Daxxify |
| Kiniksa Pharmaceuticals International, Plc | $45.70 | 2024 | Arcalyst |
| Pfizer INC. | $40.38 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.51 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $28.72 | 2021-2023 | |
| Abiomed | $19.93 | 2024 | Impella |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $18.52 | 2023 | Watchman Access System |
| Daiichi Sankyo INC. | $13.51 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.50 | 2021 | |
| Esperion Therapeutics, INC. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Polilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.